Plasma endothelin-1 level, measured glomerular filtration rate and effective renal plasma flow in diabetic nephropathy

References

• Parchwani DN, Upadhyah AA. Diabetic nephropathy: Progression and pathophysiology. Int J Med Sci Public Health. 2012;1(2):59–70
   Google Scholar
• Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: Data from 10 registries in Europe (1991–2000). Kidney Int. 2005;67:1489–1499
   PubMed Web of Science ®Google Scholar
• Cooper M. Interaction of metabolic and hemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44:1957–1972
   PubMed Web of Science ®Google Scholar
• Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4:444–452
   PubMedGoogle Scholar
• Lee GS. Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: Focus on hypertension and proteinuria. Ann Acad Med Singap. 2005;34:24–30
   PubMedGoogle Scholar
• Wolf G. New insights into the pathophysiology of diabetic nephropathy: From hemodynamics to molecular pathology. Eur J Clin Invest. 2004;34:785–796
   PubMed Web of Science ®Google Scholar
• Ergul A. Endothelin-1 and diabetic complications: Focus on the vasculature. Pharmacol Res. 2011;63:477–482
   PubMed Web of Science ®Google Scholar
• Barton M. The discovery of endothelium-dependent contraction: The legacy of Paul M. Vanhoutte. Pharmacol Res. 2011;63:455–462
   PubMedGoogle Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415
   PubMed Web of Science ®Google Scholar
• Barton M, Kohan DE, (eds). Endothelin in renal physiology and disease. Contrib Nephrol. Basel: Karger; 2011:139–148
   Google Scholar
• Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev. 2011;91:1–77
   PubMed Web of Science ®Google Scholar
• Kohan DE. Endothelin, hypertension and chronic kidney disease: New insights. Curr Opin Nephrol Hypertens. 2010;19:134–139
   PubMed Web of Science ®Google Scholar
• Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967–972
   PubMedGoogle Scholar
• Kakizawa H, Itoh M, Itoh Y, et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism. 2004;53(5):550–555
   PubMed Web of Science ®Google Scholar
• Ak G, Buyukberber S, Sevinc A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with type 2 diabetes mellitus. J Diabet Complications. 2001;15:150–157
   Google Scholar
• Zanatta CM, Veronese FV, Loreto Mda S, et al. Endothelin-1 and endothelin a receptor immunoreactivity is increased in patients with diabetic nephropathy. Renal Failure. 2012;34(3):308–315
   PubMed Web of Science ®Google Scholar
• Liakopoulos V, Wurth P, Mertens PR, et al. Endothelin-1 plasma levels in hemodialysis treatment - the influence of type 2 diabetes. Renal Failure. 2005;27(5):515–522
   PubMed Web of Science ®Google Scholar
• Ottosson-Seeberger A, Ahlborg G, Hemsén A, Lundberg JM, Alvestrand A. Hemodynamic effects of endothelin-1 and big endothelin-1 in chronic hemodialysis patients. J Am Soc Nephrol. 1999;10(5):1037–1044
   PubMedGoogle Scholar
• Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet. 1989;1:991–992
   PubMed Web of Science ®Google Scholar
• Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun. 2004;8:759–769
   Web of Science ®Google Scholar
• Schernthaner G, Erd W, Ludwig H, Sinzinger H, Höfer R. Study of age and sex dependance in renal clearances with radioisotopes. Aktuelle Gerontol. 1976;6(3):139–145
   PubMedGoogle Scholar
• Blaufox M, Frohmuller H, Campbell J, Utz D, Orvis A, Owen CA. Simplified method of estimating renal function with iodohippurate 131I. J Surg Res. 1963;3:l22–125
   Google Scholar
• Simundic AM. Practical recommendations for statistical analysis and data presentation in Biochemia Medica Journal. Biochem Med. 2012;22:15–23
   Web of Science ®Google Scholar
• Djindjic B, Rankovic G, Živic M, Savic T, Spasic M, Bubanj M. Gender difference in hipolipemic and anti-inflammatory effects of statins in diabetics with coronary artery disease. Vojnosanitet. 2009;66(12):966–972
   PubMedGoogle Scholar
• Lam HC. Role of endothelin in diabetic vascular complications. Endocrine. 2001;14(3):277–284
   PubMedGoogle Scholar
• Drakopoulos A, Goumenos DS, Vlachojannis JG, Tsakas S. Endothelin receptors in the kidney of patients with proteinuric and non-proteinuric nephropathies. Renal Failure. 2006;28:461–467
   PubMed Web of Science ®Google Scholar
• Mishra R, Emancipator SN, Kern TS, Simonson MS. Association between endothelin-1 and collagen deposition in db/db diabetic mouse kidneys. Biochem Biophys Res Commun. 2006;339:65–70
   PubMedGoogle Scholar
• Seligman BG, Biolo A, Biolo A, Polancyk CA, Gross JL, Clausell N. Increased plasma levels of endothelin 1 and von Wilenbrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000;23:1395–1400
   PubMed Web of Science ®Google Scholar
• Lee YJ, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria. Diabetes Care. 1994;17(4):263–266
   PubMedGoogle Scholar
• Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int. 2000;58:1534–1545
   PubMed Web of Science ®Google Scholar
• Jauregui A, Mintz DH, Mundel P, Fornoni A. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens. 2009;18:539–545
   PubMedGoogle Scholar
• Potenza MA, Addabbo F, Montagnani MM. Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab. 2009;297(3):568–577
   Google Scholar
• Macías-Cervantes MH, Kornhauser C, Pérez-Luque EL, Garay-Sevilla ME, Rivera-Cisneros AE. Urinary levels of endothelin-1 in type 2 diabetes mellitus patients: A non-defined marker of early renal damage. Rev Mex Patol Clin. 2008;55:42–47
   Google Scholar
• Denton KM, Shweta A, Finklestein L, Floerr RL, Evans RG. Effect of endothelin-1 on regional kidney blood flow and renal arteriole caliber in rabbits. Clinic Exp Pharmacol Physiol. 2004;31:494–501
   PubMedGoogle Scholar
• Dhaun N, Webb DJ. The road from AKI to CKD: The role of endothelin. Kidney Int. 2013;84:637–638
   PubMedGoogle Scholar
• Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ. Hemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22:3228–3234
   PubMed Web of Science ®Google Scholar
• Saeed A, Dibona GF, Guron G. Effects of endothelin receptor antagonists on renal hemodynamics in angiotensin II-infused rats on high NaCl intake. Kidney Blood Press Res. 2012;36:258–267
   PubMedGoogle Scholar
• Zanatta CM, Gerchman F, Burttet L, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80:299–303
   PubMed Web of Science ®Google Scholar
• Bruno CM, Meli S, Marcinno M, Ierna D, Sciacca C, Neri S. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. J Biol Regul Homeost Agents. 2002;16:114–117
   PubMed Web of Science ®Google Scholar
• Vermes I, Spooren PF, Kalsbeek-Batenburg EM, Haanen C. In addition to von Willebrand factor and urinary albumin excretion, plasma endothelin is an indicator of endothelial dysfunction in diabetes mellitus. Diabetologia. 1993;36:472–473
   PubMed Web of Science ®Google Scholar
• Morigi M, Buelli S, Angioletti S, et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: Implication for permselective dysfunction of chronic nephropathies. Am J Pathol. 2005;166:1309–1320
   PubMed Web of Science ®Google Scholar
• Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109:1186–1193
   PubMed Web of Science ®Google Scholar